Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma (AA007)
Allergic Asthma

About this trial
This is an interventional treatment trial for Allergic Asthma focused on measuring Omalizumab, IgE, Asthma
Eligibility Criteria
Inclusion Criteria:
- Male or female aged 15~65 years
- Written informed consent provided
- Total serum IgE >=60IU/ml
- Duration of allergic asthma >= 1 year according to GINA(2008)
- Poor response to moderate to high dose inhaled corticosteroid (400ug/day~800ug/day) >= 4 weeks
- Agreed to be not pregnant, contraception during study and later 6 months.
Exclusion Criteria:
Patients who met the below criteria were excluded:
- Be regular smokers(>10 cigarettes per day and for at least 2 years)
- Patients who are currently pregnant or nursing or intend to become pregnant over the course of the study or later 6 months
- COPD, according to the guideline of Chinese society of respiratory diseases
- An active lung disease other than allergic asthma
- Patients with significant underlying medical conditions
- Allergic to immunoglobin or any formulation ingredient of the product
- Patients with diabetes or uncontrolled hypertension(Systolic blood pressure>160mmHg or Diastolic blood pressure>95mmHg)
- HIV positivity or cancer patient
- Prior exposure to Xolair
Sites / Locations
- China-Japan Friendship Hospital
- Beijing Chaoyang Hospital
- Peking Union Medical College Hospital
- Peking University People's Hospital
- The Second Hospital of Jilin University
- West China Hospital, Sichuan University
- Chongqing Xinqiao Hospital
- Chinese PLA Fuzhou General Hospital of Nanjing Military Command
- South Hospital of South Medical University
- Sir Run Run Shaw Hospital of Zhejiang University
- The First Affiliated Hospital of Zhejiang University
- The Second Affiliated Hospital of Zhejiang University
- Chinese PLA Jinan Military General Hospital
- Shandong Provincial Hospital
- Jiangsu Province Hospital
- Zhongda Hospital, Southeast University
- The First Affiliated Hospital of Guangxi Medical University
- Qingdao Municipal Hospital
- Shanghai Changzheng Hospital
- Shanghai First People's Hospital
- Zhongshan Hospital, Fudan University
- Chinese PLA Shenyang Military Command General Hospital
- The First hospital of China Medical University
- The Second Hospital of Hebei Medical University
- The Second Hospital of Tianjin Medica University
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and technology
- Xi'an Xijing Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Omalizumab
placebo
During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the following treatment phase, patients continued to receive optimized BUD and Omalizumab for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks. The dosage of Omalizumab received was based on body weight and serum IgE.
During the 4~6-week Run-in phase, the dosage of budesonide inhaled powder(BUD) was prescribed and optimized to maintain asthma control according to Global Initiative for Asthma(GINA, 2008) guidelines. During the treatment phase, patients continued to receive placebo and optimized BUD for 28 weeks, administered by subcutaneous injection every 2 weeks or 4 weeks.